0J4V.LSE Heron Therapeutics Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -393.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0J4V.LSE undervalued?
Graham numberThe Graham number of Heron Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Heron Therapeutics Inc. fundamental analysis
No fundamental analysis for Heron Therapeutics Inc. yet.
Heron Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Heron Therapeutics Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of…
Full company profileHeron Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Heron Therapeutics Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.28M | 30.8M | 77.5M | 146M | 88.6M | 86.3M | 108M | 127M | 144M | 155M | 145M |
| Gross Profit | 145K | 26.2M | 50.0M | 84.3M | 52.4M | 40.3M | 52.8M | 10.0M | 106M | 114M | 100M |
| Operating Income | -163M | -193M | -184M | -211M | -228M | -216M | -169M | -111M | -11.5M | -2.54M | -13.6M |
| EBITDA | -170M | -193M | -182M | -209M | -223M | -215M | -177M | -104M | -5.06M | -224K | -11.7M |
| Net Income | -173M | -197M | -179M | -205M | -227M | -221M | -182M | -111M | -13.6M | -20.2M | -27.2M |
| EPS | -4.57 | -3.65 | -2.44 | -2.50 | -2.50 | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 | -0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 67.5M | 234M | 462M | 513M | 354M | 306M | 251M | 223M | 233M | 671M | 252M |
| Total Liabilities | 88.7M | 103M | 92.0M | 109M | 117M | 228M | 237M | 256M | 267M | 657M | 245M |
| Shareholders' Equity | -21.3M | 131M | 370M | 404M | 236M | 77.6M | 13.6M | -34.0M | -33.7M | 14.3M | 6.91M |
| Cash & Short-term Investments | 51.1M | 172M | 332M | 391M | 208M | 158M | 84.9M | 80.4M | 59.3M | 46.6M | 42.7M |
| Total Debt | 52.9M | 28.7M | 4.57M | 19.8M | 24.6M | 159M | 157M | 180M | 178M | 141M | 148M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -134M | -170M | -192M | -125M | -185M | -203M | -147M | -58.8M | -22.5M | -27.6M | -7.51M |
| Capital Expenditure | 3.14M | 2.55M | 9.17M | 7.15M | 6.81M | 3.02M | 1.83M | 1.55M | 1.71M | 317K | 1.06M |
| Free Cash Flow | -137M | -173M | -201M | -132M | -192M | -206M | -149M | -60.3M | -24.2M | -27.9M | -8.56M |
| Ratios | |||||||||||
| ROE | - | -150.6% | -48.3% | -50.7% | -96.1% | -284.5% | -1,341.2% | - | - | -140.9% | -393.7% |
| ROA | -256.6% | -84.3% | -38.7% | -39.9% | -64.3% | -72.2% | -72.5% | -49.7% | -5.8% | -3.0% | -10.8% |
| Net Profit Margin | -13,537.4% | -641.9% | -230.8% | -140.3% | -256.4% | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% | -18.8% |
| Debt to Equity | - | 0.22x | 0.01x | 0.05x | 0.10x | 2.06x | 11.60x | - | - | 9.81x | 21.48x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Heron Therapeutics Inc. dividends
Heron Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Who owns Heron Therapeutics Inc.
- Insiders 0.99%
- Institutions 70.12%
- Public & others 28.89%
- Free float 147M
Heron Therapeutics Inc. company profile
- Company name
- Heron Therapeutics Inc.
- Ticker
- 0J4V.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 128
- Fiscal year end
- December
- Address
- 25 Fenton Main Street, Cary, NC, United States, 27511
- Phone
- 858 251 4400
- Website
- herontx.com
About Heron Therapeutics Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeutics Inc. management
10- Mr. Craig Alexander CollardCEO & Director · born 1966
- Ms. Ira DuarteExecutive VP & CFO · born 1969
- Mr. Mark E. HensleyExecutive VP & COO · born 1983
- Dr. William P. Forbes Pharm. D., Pharm.D.Executive VP & Chief Development Officer · born 1962
- Melissa JarelVice President of Legal
- Mr. Ryan CraigVice President of Marketing
- Mr. John AikenExecutive Director of People Management & Training
- Dr. John C. Arthur Ph.D.Senior Vice President of Manufacturing Development · born 1966
- Mr. Robert SullivanChief Commercial Officer · born 1978
- Mr. Brett FleshmanChief Business Officer